SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to mixed reactions to its Q3 earnings, with discussions focused on improved margins versus lowered Q4 delivery guidance; the community is debating whether margin improvements outweigh concerns about future growth, and some believe the CEO's guidance is negatively impacting the stock.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet ($GOOG) is trending as community sentiment turns bullish, fueled by hype around their Gemini AI model and potential competition with Nvidia ($NVDA) in AI chips. Discussions center on Google's AI leadership and the possibility of Meta ($META) utilizing Google's TPUs, shifting the competitive landscape. Some traders are noting the rapid price increase and questioning if it's overextended, while others believe this is only the beginning.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is facing downward pressure amid reports of Meta considering Google's AI chips, sparking concerns about increased competition in the AI chip market. The community is debating the potential impact of Google's TPUs on NVIDIA's dominance, with some viewing it as a long-term threat while others believe NVIDIA's ecosystem and existing contracts will sustain its leadership. Broader market context includes discussions of an AI bubble and potential market rotation.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending downwards amidst discussions about AI chip competition and potential market share shifts, particularly with Google entering the arena. The community is debating whether this sell-off is an overreaction or a sign of weakening fundamentals, with some seeing it as a buying opportunity and others anticipating further declines. Broader market factors, including potential interest rate cuts and overall AI sector sentiment, are also influencing the conversation.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as investors weigh strong AI and cloud growth against mixed earnings, with focus on Qwen's rapid adoption and the potential for further AI investment. Community chatter highlights debate about earnings and long-term value, especially compared to US hyperscalers. Recent news regarding a White House memo alleging the company provides tech support for Chinese military is also impacting discussion.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as enthusiasm builds around its AI capabilities, particularly Gemini, with chatter suggesting it may surpass competitors. A potential deal with Meta to utilize Google's TPUs is fueling optimism, positioning GOOGL as a strong contender in the AI landscape. Community members are discussing the possibility of GOOGL reaching new all-time highs and a $4 Trillion market cap.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending amid reports of a growing partnership with Google on its TPU chips, positioning it as a key player in custom silicon for AI. Community discussions highlight potential revenue growth and a possible challenge to Nvidia's dominance, while analysts maintain a bullish outlook ahead of upcoming earnings. Sentiment suggests a rotation into AVGO from other semiconductor stocks as investors weigh the implications of custom chip strategies in the AI landscape.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's is trending due to positive sentiment following raised profit forecasts and a potential short squeeze, leading to active discussions about its valuation and future potential. Community members are debating whether the stock can sustain its momentum and achieve higher price targets. Some are pointing to the company's real estate value and potential as reasons for optimism.

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, EMEA and APAC. The Americas segment includes operations in North America and South America. The EMEA segment includes operations in Europe, the Middle East and Africa. The APAC segment includes operations in the Asia-Pacific region, including Asia and Oceania. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH.

Abercrombie & Fitch Co. - Ordinary Shares - Class A

Abercrombie & Fitch Co.

Abercrombie & Fitch is trending due to a significant post-earnings selloff, despite initially positive reactions and strong Q1 results. The community is actively discussing whether this dip represents a buying opportunity, given the company's buyback program and low valuation, or if it signals deeper concerns about margins and brand performance. Discussions also include potential connections with broader market factors like tariff uncertainties and sector-wide trends affecting retail apparel.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM is trending due to ongoing discussions about a potential takeover, fueled by a strategic review initiated by the board, which includes evaluation of takeover offers. Community members are weighing in on possible buyout prices and the potential for a short squeeze, while also considering the impact of shipping rates and the company's cash position. Speculation is high, with some seeing a generational opportunity and others expressing concern over management's intentions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Both subcutaneous and oral Amycretin appeared to have a safe and well-tolerated profile in the study, Novo said.</li><li>Novo is now planning to initiate a late-stage trial of Amycretin in patients with type 2 diabetes in 2026.&nbsp;</li><li>The positive announcement comes on the heels of the company's discontinuation of late-stage trials of its GLP-1 drug, Semaglutide, in Alzheimer’s disease.</li></ul> Novo Nordisk (NVO) on Tuesday said that a mid-stage trial evaluating Amycretin in people with type 2 diabetes yielded positive outcomes in both weight loss and reduction in average blood sugar levels.NVO shares traded 3% higher in the pre-market session at the time of writing.<h2 class="st-heading-2">Study Outcomes</h2>Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeks, as compared to 2.6% in patients treated with placebo, and demonstrated statistically significant reductions in average blood sugar levels, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/25/3194155/0/en/Novo-Nordisk-phase-2-trial-with-amycretin-reports-significant-weight-loss-and-HbA1c-reduction-in-type-2-diabetes.html">said</a>.The trial investigated the efficacy, safety, and pharmacokinetics of once-weekly subcutaneous Amycretin and once-daily oral amycretin compared with placebo in 448 people with type 2 diabetes inadequately controlled on metformin. About 40% of the study participants also used a class of drugs known as SGLT2 inhibitors to manage their diabetes before joining the study.Amycretin belongs to the class of drugs known as GLP-1s, used to treat diabetes and obesity, similar to Novo’s blockbuster drugs Wegovy and Ozempic. Both subcutaneous and oral Amycretin appeared to have a safe and well-tolerated profile in the study, Novo said. The common side effects were gastrointestinal, and the vast majority were mild to moderate in severity, the company added.<h2 class="st-heading-2">Plans Ahead</h2>Novo is now planning to initiate a late-stage trial of Amycretin in patients with type 2 diabetes in 2026.Chief Scientific Officer Martin Holst Lange noted that this is the first time Amycretin has been evaluated in this population and added that the company is planning to test the GLP-1 compound across multiple indications starting next year.The positive announcement comes on the heels of the company's discontinuation of late-stage trials of its GLP-1 drug, Semaglutide, in Alzheimer’s disease.The company said on Monday that its late-stage trials evaluating oral Semaglutide in Alzheimer’s disease did not confirm its superiority over placebo in slowing disease progression, and it is subsequently discontinuing them.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVO jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down by 48% this year and by about 57% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/autl-stock-soars-pre-market-on-position-recommendation-for-cell-therapy-targeting-cancer-in-uk/cL52LfPREXA">AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study

The trial was investigating the efficacy, safety, and pharmacokinetics of once-weekly subcutaneous amycretin and once-daily oral amycretin compared to placebo in 448 people with type 2 diabetes. 

Equity

<ul class="summary-bullets"><li>Semaglutide is the active ingredient in Novo’s blockbuster drugs Wegovy and Ozempic.&nbsp;</li><li>The company said it decided to test the drug in Alzheimer’s disease based on real-world evidence and preclinical models.</li><li>The company conducted two late-stage studies in Alzheimer’s disease, and while an improvement of disease-related biomarkers was observed in both trials with Semaglutide, it did not delay the progression of the disease.</li></ul>Novo Nordisk (NVO) on Monday said that its late-stage trials evaluating oral Semaglutide in Alzheimer’s disease did not confirm its superiority over placebo in slowing disease progression.Shares of the company slumped 11% in the pre-market session at the time of writingSemaglutide is the active ingredient in Novo’s blockbuster weight-loss drug Wegovy. The company said that it decided to test the drug in Alzheimer’s based on real-world evidence studies, pre-clinical models, as well as post-hoc analyses from diabetes and obesity trials. The compound, belonging to the category known as GLP-1 drugs, is marketed as Ozempic and Rybelsus for the treatment of type 2 diabetes as well.<h2 class="st-heading-2">Trial Outcomes</h2>The company conducted two late-stage studies in Alzheimer’s disease, and while an improvement of disease-related biomarkers was observed in both trials with Semaglutide, it did not delay the progression of the disease, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193328/0/en/Novo-Nordisk-A-S-Evoke-phase-3-trials-did-not-demonstrate-a-statistically-significant-reduction-in-Alzheimer-s-disease-progression.html">said</a>. The two trials enrolled a total of 3,808 adults and were aimed at evaluating the efficacy and safety of oral Semaglutide compared to placebo on top of standard of care in early-stage symptomatic Alzheimer’s disease.Alzheimer’s is a leading cause of memory loss or dementia. It is a progressive disease where symptoms gradually worsen over time. Semaglutide appears to have a safe and well-tolerated profile in the studies with patients aged 55-85 suffering from mild cognitive impairment or mild dementia due to Alzheimer’s disease, Novo noted.The company said that it is discontinuing the trials. However, the data generated will continue to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities, it added. The data from the trials will also be presented at future conferences, the company said.<h2 class="st-heading-2">Semaglutide And Its Many Indications</h2>Semaglutide is Novo's biggest asset. In the nine months through the end of September, the company reported sales of DKK 95.264 billion ($14.721.52 billion) from Ozempic, DKK 16.790 billion from Rybelsus and DKK 57.242 billion from Wegovy, togetherly accounting for about 74% of the company’s overall sales in the period.&nbsp;An approval in Alzheimer’s could have helped the company ramp revenue from the compound as its rivalry with American GLP-1 drugmaker Eli Lilly intensifies.&nbsp;The company’s drop in share price prompted a change in CEO earlier this year and layoffs.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVO stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 45% this year and by 54% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/btc-holds-86000-crypto-market-back-above-3-trillion-xrp-doge-gain/cL5bex0REQP">Bitcoin Holds $86,000 With Crypto Market Back Above $3 Trillion – XRP, Doge Gain Ahead Of Grayscale’s New ETF Launches</a>For updates and corrections, email newsroom[at]stocktwits[dot]comExchange Rate: DKK1= $0.15

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies

The company said that it is discontinuing the trials.

BioNTech SE (BNTX) announced on Friday that a late-stage trial, conducted by its partner Duality Biologics in China, has met its primary endpoint of progression-free survival at a pre-specified interim analysis. The trial is evaluating Trastuzumab Pamirtecan versus Trastuzumab Emtansine in patients with certain types of breast cancer.Shares of the company traded 10% higher in the pre-market session on Friday. The <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biontech.de/news-releases/news-release-details/biontech-and-dualitybio-announce-phase-3-trial-adc-candidate">trial</a> enrolled 228 patients with HER2-positive unresectable or metastatic breast cancer, an aggressive form of the disease that has spread and cannot be surgically removed, who previously received Trastuzumab and a taxane-based chemotherapy.On Stocktwits, retail sentiment around BNTX stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_05_at_8_57_36_AM_png_5a9988a80e.webp" alt="BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits</figcaption></figure> DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.DualityBio Global Medical Officer Hua Mu noted that breast cancer has a high incidence rate in China, with over 350,000 new cases annually.“Together with our partner BioNTech, we plan the development of Trastuzumab Pamirtecan in further tumor types towards BLA application in other regions including the United States and the European Union to maximize its potential for patients around the world,” Mu said.BioNTech also noted that this is the first positive late-stage data readout achieved in the collaboration between the two companies initiated in April 2023. The collaboration aims to accelerate the development of differentiated antibody drug-conjugate therapeutics for solid tumors.BioNTech holds global commercial rights for Trastuzumab Pamirtecan, while DualityBio has commercial rights for Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region.BNTX stock is down by 9% this year but up by about 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-proposes-whopping-1-trillion-pay-package-for-ceo-elon-musk/chwIJkaRdpr">Tesla Proposes Whopping $1 Trillion Pay Package For CEO Elon Musk</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioNTech logo is displayed on a smartphone screen. (Photo illustration by Cheng Xin/Getty Images)

Why Did BioNTech Stock Surge 10% Pre-Market Today?

DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.

Sanofi (SNY) announced on Thursday that its experimental drug, Amlitelimab, met all primary and key secondary endpoints in a late-stage study in adults and adolescents with atopic dermatitis (AD).The <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-09-04-05-00-00-3144170">study</a> enrolled 601 adults and adolescents aged 12 years and older with moderate-to-severe AD. Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically meaningful efficacy in skin clearance and disease severity compared to placebo at week 24. Furthermore, a progressive increase in efficacy was observed during the treatment period in patients who were dosed every four weeks as well as in those who were dosed every 12 weeks, the company said.The most common treatment-emergent adverse events, such as upper respiratory tract infection, were more common in the placebo arm compared to the Amlitelimab-treated arms of the study, it said.Shares of the company, however, traded 9% lower in the premarket session at the time of writing.According to a Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-sheds-13-billion-value-weak-trial-results-eczema-drug-2025-09-04/">report</a>, Jefferies analysts opined that the trial results fell short of those from an earlier trial and of rival biologic drugs. However, the drug's safety profile and convenient 12-week dosing regimen could still support its use.JPMorgan, meanwhile, noted that the data confirmed that Amlitelimab is less effective than Sanofi’s approved drug Dupixent, Reuters added. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SNY">SNY stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:578/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_04_at_7_50_44_AM_png_2f5aa98d10.webp" alt="SNY's Sentiment Meter and Message Volume as of 7:51 a.m. ET on Sept. 4, 2025 | Source: Stocktwits" width="578" height="61"><figcaption>SNY's Sentiment Meter and Message Volume as of 7:51 a.m. ET on Sept. 4, 2025 | Source: Stocktwits</figcaption></figure>Sanofi’s Dupixent is approved to treat atopic dermatitis in addition to asthma, chronic spontaneous urticaria, and other diseases. In the second quarter, Dupixent sales increased by 21.1% to €3.8 billion ($4.43 billion), and the company was expecting Amlitelimab to complement the blockbuster drug.The firm now looks forward to sharing additional late-stage results from the clinical development program of Amlitelimab in atopic dermatitis, said Houman Ashrafian, Executive Vice President, Head of Research &amp; Development at Sanofi.SNY stock is up 3% this year but down approximately 15% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/fda-says-no-advisory-commitee-meeting-required-for-aquestive-oral-epinephrine-film/chwd20pRdYB">FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Exchange Rate: €1= $1.17

Photo taken on April 15, 2025 shows the pharmaceutical factory of pharmaceutical company Sanofi in Hangzhou, Zhejiang province, China. (Photo credit should read CFOTO/Future Publishing via Getty Images)

Sanofi’s New Experimental Eczema Drug Meets Goals Of Late-stage Trial, But Wall Street Expected More

Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically meaningful efficacy in skin clearance and disease severity compared to placebo at week 24, the company said. 

A Delaware federal judge on Friday reportedly said that Novartis (NVS) cannot block India-based drugmaker MSN Pharmaceuticals from launching a generic version of its heart failure drug Entresto before its patent expires late next year.The judge rejected Novartis’ argument that the generic would infringe on one of the company’s patents, Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/novartis-loses-bid-block-us-entresto-generic-through-2026-2025-07-11/">reported</a>. U.S. District Judge Richard Andrews also denied Novartis’ request to block the generic from launching until after the patent expires in November 2026.NYSE-listed shares of <a href="https://stocktwits.com/symbol/NVS">Novartis</a> were trading 2% lower at the time of writing.Novartis told Reuters in a statement that it plans to appeal.The company told the court in a filing on Friday that MSN may receive the U.S. Food and Drug Administration’s approval for the generic as soon as July 16 and launch it soon after, cutting into the market for Entresto.Entresto is a prescription medicine used to treat adults with long-lasting (chronic) heart failure to help reduce the risk of death and hospitalization. It was Novartis’s best-selling brand in the first quarter.The company reported $2.26 billion in net sales for the drug, marking a growth of 22% at constant currency. The drug, in fact, accounted for over 17% of the company’s overall net sales in the period.The company said in April that the drug had sustained, robust, demand-led growth globally in the quarter, including in China and Japan, with increased penetration in hypertension.On Stocktwits, retail sentiment around Novartis remained unmoved in the ‘neutral’ territory over the past 24 hours while message volume stayed unchanged at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:622/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_2_12_01_PM_png_5d097b2dd4.webp" alt="NVS's Sentiment Meter and Message Volume as of 2:10 p.m. ET on July 11, 2025 | Source: Stocktwits" width="622" height="66"><figcaption>NVS's Sentiment Meter and Message Volume as of 2:10 p.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure>NVS stock is up by about 25% this year and by about 10% over the past 12 months.Read Next: <a target="_blank" rel="noopener noreferrer nofollow" href="https://CMS’s Initial Proposal To Cover Renal Denervation A Win For Medtronic, Says Analysts">CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Fails To Block Heart Failure Drug’s Generic From Launching Through 2026: Report

Novartis’ heart failure drug Entresto accounted for over 17% of the company’s overall net sales in the first quarter of 2025.

Novartis (NVS) on Tuesday said that Swiss authorities have approved its Coartem Baby as the first malaria medicine for newborns and young infants.<a href="https://stocktwits.com/symbol/NVS">Novartis</a> developed the treatment, also known as Riamet Baby in some geographies, in collaboration with Medicines for Malaria Venture (MMV).The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-receives-approval-first-malaria-medicine-newborn-babies-and-young-infants">said</a> that it now expects rapid approval for the treatment in eight African countries, including Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Uganda, and Tanzania. &nbsp;Malaria is a life-threatening disease caused by a parasite and spread to humans by some types of mosquitoes. Novartis cited WHO data and noted that there were 263 million cases of malaria and 597,000 deaths in 2023, almost all of them in Africa.&nbsp;The company said it intends to introduce the infant-friendly treatment on a largely not-for-profit basis where malaria is endemic. According to Novartis, some 30 million babies are born in areas of malaria risk in Africa every year.The new approval is for the treatment of malaria in infants weighing between 2kg and 5kg. Novartis said there were no approved malaria treatments for infants weighing less than 4.5kg until now, leaving a treatment gap. Furthermore, malaria vaccines are also not approved for the youngest babies, the company noted.The pediatric formulation of the treatment is dissolvable, including in breast milk, and has a sweet cherry flavor to make it easier to administer.“The approval of Coartem Baby provides a necessary medicine with an optimized dose to treat an otherwise neglected group of patients and offers a valuable addition to the antimalarial toolbox,” CEO of MMV Martin Fitchet said.On Stocktwits, retail sentiment around Novartis is trending in the “bullish” territory, coupled with “high” message volume.<figure class="image"><img style="aspect-ratio:1250/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_08_at_7_32_02_AM_png_2a581d344f.webp" alt="NVS's Sentiment Meter and Message Volume as of 7:30 a.m. ET on July 8, 2025 | Source: Stocktwits" width="1250" height="130"><figcaption>NVS's Sentiment Meter and Message Volume as of 7:30 a.m. ET on July 8, 2025 | Source: Stocktwits</figcaption></figure>NVS stock is up by about 26% this year and by 13% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/musk-ally-isaacman-reacts-to-trump-s-political-jabs-says-nasa-without-a-confirmed-leader-not-ideal-for-america/chFvNyDR5g4">Musk Ally Isaacman Reacts To Trump’s Political Jabs, Says NASA Without A Confirmed Leader ‘Not Ideal For... America’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novartis Gets Swiss Authority Nod For First Malaria Drug In Newborns, Young Infants

The company said that it now expects rapid approval for the treatment in eight African countries, including Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Uganda, and Tanzania. 

Medicine company Novartis (NVS) said on Thursday that a late-stage trial evaluating its drug Cosentyx in adults with newly diagnosed or relapsing giant cell arteritis failed to meet its primary goal of sustained remission. &nbsp;Cosentyx was evaluated in combination with a 26-week steroid taper and compared to placebo plus a 52-week steroid taper in the trial. The drug, however, did not demonstrate a statistically significant improvement in sustained remission at week 52 compared to placebo.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-gcaptain-study-cosentyx-giant-cell-arteritis-gca">said</a> that it will share a full evaluation of the trial data at a later date.Shares of Novartis were trading 1% lower in the pre-market session.Giant cell arteritis (GCA) is the most common form of systemic vasculitis, a group of rare autoimmune diseases characterized by inflammation of blood vessels. GCA primarily affects people over 50 years of age and has the potential to cause irreversible vision loss and life-threatening aortic aneurysms.Cosentyx, launched in 2015, is already approved for use in adults with multiple conditions such as psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa.It is also approved in pediatric patients with moderate to severe plaque psoriasis, enthesitis-related arthritis, and juvenile psoriatic arthritis.In the first quarter of 2025, Cosentyx brought in $1,534 million in net sales, marking a growth of 18% at constant currency, as sales grew mainly in the U.S., emerging markets, and Europe.Cosentyx, in fact, accounted for about 12% of the company’s overall net sales in the quarter.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVS">Novartis</a> jumped from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_03_082008_png_2cf306955c.webp" alt="NVS's Sentiment Meter and Message Volume as of 8:20 a.m. ET on July 3, 2025 | Source: Stocktwits" width="627" height="57"><figcaption>NVS's Sentiment Meter and Message Volume as of 8:20 a.m. ET on July 3, 2025 | Source: Stocktwits</figcaption></figure>NVS stock is up by over 27% this year and by about 16% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/alibaba-targets-1.5-billion-from-bond-sale-linked-to-health-arm/chFjAFkRcmI">Alibaba Targets $1.5B From Bond Sale Linked To Health Arm: Retail’s Buoyant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novartis’ Blockbuster Drug Fails Late-Stage Trial In Disease Causing Blood Vessel Inflammation, But Retail Turns Bullish

Giant cell arteritis (GCA) is the most common form of systemic vasculitis, a group of rare autoimmune diseases characterized by inflammation of blood vessels.

U.S. District Judge Mark Pittman in Fort Worth, Texas, reportedly upheld the U.S. Food and Drug Administration's (FDA) decision on Wednesday to remove Novo Nordisk's popular drugs, Ozempic and Wegovy, from its shortage list.Pittman said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list while rejecting a challenge brought by compounding pharmacies who sought to continue making copies of the drugs, Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-judge-upholds-fdas-removal-ozempic-wegovy-drug-shortage-list-2025-06-18/">reported</a>.Compounders are allowed to produce copies of drugs only when they are declared to be in short supply by the FDA. In February, the FDA announced that the semaglutide injection product shortage had been resolved, preventing compounders from manufacturing copies of Wegovy and Ozempic, as semaglutide is the active ingredient in them.Semaglutide injection products were first added to the FDA’s drug shortage list in 2022, paving the way for compounders to replicate them.Late last month, Novo Nordisk said that it had filed nearly 120 lawsuits across 34 states against compounders and other entities making false and misleading claims about their “semaglutide" drugs.The company also announced a $199-per-month limited-time offer for self-paying patients new to its weight loss drug, Wegovy, to encourage patients who previously used compounded versions of the drug to transition to Wegovy.On Stocktwits, retail sentiment around Novo Nordisk shares rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:629/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_18_at_12_40_07_PM_png_8852be04e7.webp" alt="NVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on June 18, 2025 | Source: Stocktwits" width="629" height="65"><figcaption>NVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on June 18, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down by about 15% this year and by about 47% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tmc-stock-surges-to-near-4-year-high-after-opening-the-door-to-cashless-exercise-of-class-b-warrants/chlsB67RR2h">TMC Stock Surges To Near 4-Year High After Opening The Door To Cashless Exercise Of Class B Warrants</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies

The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported. 

Danish drugmaker Novo Nordisk (NVO) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916348">announced</a> on Thursday that it plans to initiate a late-stage development program with its experimental drug Amycretin for adults with obesity or those who are overweight, starting in the first quarter of 2026.Shares of NVO traded 3% higher on Thursday.The decision to advance the study of Amycretin into the late stage is based on feedback received from regulators following mid-stage studies.Amycretin is a single molecule that operates as both GLP-1 receptor agonist and amylin receptor agonist.While GLP-1 receptor agonists work by mimicking the natural hormone GLP-1, Amylin receptor agonists mimic the effects of the natural hormone amylin, reducing appetite. The drug is developed for subcutaneous and oral administration.The company’s popular weight-loss drug Wegovy’s active component is Semaglutide, another GLP-1 receptor agonist.In the first quarter, Wegovy experienced an 85% increase in sales to DKK 17.36 billion ($2.69 billion), while the company’s overall sales within its obesity care segment grew 67% to DKK 18.42 billion.However, last month, the company said that Lars Fruergaard Jørgensen will <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-ceo-to-step-down/chiw5m5Rbno">step down</a> as CEO as per a mutual agreement with the Novo Nordisk board.The board stated that the change is being made in light of Novo Nordisk's recent market challenges, the company’s declining share price since mid-2024, and discussions with the Novo Nordisk Foundation.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> has fallen by about 8% this year and by about 44% over the past 12 months.On Stocktwits, retail sentiment around Novo Nordisk stayed unmoved within the ‘bullish’ territory over the past 24 hours while message volume remained ‘high’.<figure class="image"><img style="aspect-ratio:628/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_12_at_2_12_25_PM_png_81063cab85.webp" alt="Screenshot 2025-06-12 at 2.12.25 PM.png" width="628" height="64"><figcaption>NVO's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Jun 12, 2025 | Source: Stocktwits</figcaption></figure>Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/google-cloud-teams-up-with-databricks-to-scale-gemini-enterprise-adoption/chlgdNHRRGd">Google Cloud Teams Up With Databricks To Scale Gemini Enterprise Adoption</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.(Exchange Rate: 1 DKK= 0.16 USD)

Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking

The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from regulators following mid-stage studies.

Mesoblast (MESO) <a target="_blank" rel="noopener noreferrer nofollow" href="https://investorsmedia.mesoblast.com/static-files/45831458-f1fc-48e1-ae2c-ede16ee03af2">said</a> on Thursday it is awaiting the final minutes from the U.S. Food and Drug Administration (FDA) to provide timelines for potential filing for its late-stage product candidate Revascor. Nasdaq-listed shares of the company rose over 3% by Thursday morning.The biotechnology company is seeking to file an application for the approval of Revascor for the treatment of patients with ischemic chronic heart failure, characterized by an enlarged heart and insufficient blood flow to the organs and extremities of the body. The condition is estimated to affect 2% of the adult population of the United States.During the meeting held in the first week of June, there was general alignment on items regarding chemistry, manufacturing &amp; controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval, the company said.The firm added that it is now awaiting the final minutes from the FDA to determine the timeline for a potential approval filing.The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft versus host disease (SR-aGvHD). Ryoncil is currently approved for the treatment of pediatric patients two months of age and older, and the company is looking to expand the scope of its treatment to adults.On Stocktwits, retail sentiment around Mesoblast rose from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:634/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_12_at_10_45_51_AM_png_80e25b67b7.webp" alt="MESO's Sentiment Meter and Message Volume as of 10:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits" width="634" height="63"><figcaption>MESO's Sentiment Meter and Message Volume as of 10:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the update from the company and said that it is at its “inflection point.”<stembedurl>https://stocktwits.com/Mani86/message/617651955</stembedurl><a href="https://stocktwits.com/symbol/MESO">MESO stock</a> is down by about 41% this year but up by nearly 71% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cardinal-health-raises-fy25-earnings-guidance/chlgGvBRb6x">Cardinal Health’s Improved FY25 Earnings Guidance Draws Retail Cheer, Stock Inches Toward Record Highs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’

The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease.

Buying

Holding

Selling or trimming

Watching from the sidelines

What are you doing with Alphabet ($GOOGL) stock as it hits fresh all-time highs?

APIE
Trust For Professional Managers - ActivePassive International Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest APIE News

APIETrust For Professional Managers - ActivePassive International Equity ETF